CJC-1295
Also known as: Modified GRF 1-29, CJC-1295 DAC, CJC-1295 no DAC
A long-acting growth hormone releasing hormone analog.
Overview
CJC-1295 is a synthetic analog of GHRH with amino acid substitutions that confer protease resistance. Available with or without Drug Affinity Complex (DAC) for different duration profiles.
Mechanism of Action
Binds GHRH receptors on pituitary somatotrophs, stimulating GH synthesis and release. The DAC version binds albumin for extended duration; non-DAC version provides pulsatile release.
Pharmacokinetics
CJC-1295 DAC: half-life ~8 days. CJC-1295 no DAC: half-life ~30 minutes. DAC provides sustained GH elevation; no-DAC mimics natural pulsatility.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
No-DAC Protocol
100 mcg
2-3x daily
8-12 weeks
Combined with GHRP for best results
DAC Protocol
2 mg
Once weekly
8-12 weeks
Sustained elevation approach
Stacking Recommendations
Peptides that may be combined based on complementary mechanisms in research settings.
Research Areas
Key Research Findings
- 12-10 fold increase in GH levels with DAC version
- 2IGF-1 elevation sustained for weeks
- 3Improved sleep and recovery reported
- 4No-DAC version better preserves pulsatile GH pattern
Side Effects & Contraindications
Reported Side Effects
- Flushing
- Water retention
- Numbness/tingling
Contraindications
- Active malignancy
- Diabetes (caution)
Safety Considerations
DAC version may cause sustained GH elevation which could affect glucose. Water retention and joint pain possible.
Storage Requirements
Store lyophilized at -20C
Scientific References
- 1